Delcath Systems, Inc.

NasdaqCM DCTH

Delcath Systems, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024

Delcath Systems, Inc. Return on Assets (ROA) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqCM: DCTH

Delcath Systems, Inc.

CEO	Mr. Gerard J. Michel MBA, MS
IPO Date	May 3, 2018
Location	United States
Headquarters	1633 Broadway
Employees	76
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Drugstores & Retail Pharmacies Medical Instruments Pharmaceuticals

Description

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Key trends

Past 5 years